IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
AstraZeneca PLC focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. The company serves primary care and specialty care physicians through distributors in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia.
Manufacturing
Pharmaceutical Products
$101.57B
83.5K
Pascal Soriot
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Solid dividend yield for income-focused strategies.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = AZN ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$AZN ASTRAZENECA PLC | 73 | 85 | 96 | 78 | 45.1x | 3.4x | 88.7% | 69.6% | 68.6% | 31.0% | 28.3% | 13.3% | 3.8% | 37.0x | $101.6B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
ASTRAZENECA PLC (AZN) receives a "Buy" rating with a composite score of 73.3/100. It ranks #31 out of 7,333 stocks in our coverage universe and carries a 4-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Pascal Soriot
Chief Executive Officer
Labor Force
83,500
85
43
48
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for AZN
Outperforming peers — winners tend to keep winning over 3-12 months
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Average volatility — neutral timing signal
Moderate investment profile
Top-rated overall — multiple factors aligned for strong entry
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for AZN.
View All RatingsYOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Earnings well-supported by fundamental cash flows
Improving capital utilization rates confirmed
High margin volatility — erratic forensic earnings quality
Capital Income Projection
A $10,000 capital deployment would generate approximately $377 annually in verified dividends.
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 85 | 97 | -12DRAG |
| MOMENTUM | 78 | 81 | -3NEUTRAL |
| VALUATION | 96 | 98 | -2NEUTRAL |
| INVESTMENT | 43 | 78 | -35DRAG |
| STABILITY | 48 | 30 | +18ALPHA |
| SHORT INT | 89 | 99 | -10DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC 64.0% vs WACC 9.2% (spread +54.7%)
GM 69% vs sector 43%, OM 31% vs sector 1%
Capital turnover 2.61x, R&D intensity 21.2%
Rev growth 13%, 9yr history
Interest coverage N/A, Net debt/EBITDA 1.0x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
ASTRAZENECA PLC receives a Buy rating with a composite score of 73.3/100 and 4 out of 5 stars, ranking #31 of 7,333 stocks in our universe. AZN displays a favorable combination of factors that positions it above the majority of the market. While not without risk, the quantitative profile supports a constructive outlook.
ASTRAZENECA PLC scores an outstanding 85/100 on our quality factor, placing it among the highest-quality companies in our coverage universe. The company reports a return on equity of 88.7% (sector avg: -2.5%), gross margins of 68.6% (sector avg: 42.5%), net margins of 28.3% (sector avg: -0.2%). This level of profitability and capital efficiency typically reflects a durable competitive advantage and disciplined management.
From a valuation perspective, AZN scores an exceptional 96/100, indicating the stock trades at a deep discount relative to its fundamentals. Key valuation metrics include a P/E ratio of 45.14x, an EV/EBITDA of 3.44x, a P/B ratio of 3.88x. A value score this high suggests the market may be significantly underpricing the company's earnings power, assets, or cash flow generation.
With an investment score of 43/100, AZN exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 13.3% vs. a sector average of 5.9% and a return on assets of 69.6% (sector: -0.1%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
AZN shows strong momentum characteristics with a score of 78/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at 13.3% year-over-year, while a beta of 0.55 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
With a stability score of 48/100, AZN exhibits average financial resilience. Key stability metrics include a beta of 0.55 and a debt-to-equity ratio of 37.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
AZN's short interest factor score of 89/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include elevated leverage (D/E: 37.00x). As a large-cap company with a market capitalization of $101.6B, ASTRAZENECA PLC benefits from the generally lower volatility and deeper liquidity associated with its size class.
AZN pays a solid dividend yield of 3.8%, contributing an income component to total returns. This moderate yield suggests a balance between returning capital to shareholders and retaining earnings for reinvestment — a common profile among quality compounders.
ASTRAZENECA PLC is a large-cap company in the Manufacturing sector, ranked #17 of 50 in its sector (66th percentile) and #31 of 7,333 overall (100th percentile). Key comparisons include ROE of 88.7% exceeding the -2.5% sector median and operating margins of 31.0% above the 1.3% sector average. This above-median position indicates AZN is outperforming a majority of its Manufacturing peers, though there is room to close the gap with sector leaders.
Want professional-grade coverage on AZN?
Access Premium Terminal →Quant Factor Profile
Key factor gap
Value (96) vs Investment (43) — closing this gap could shift the rating.
RANK #17 OF 50 IN INDUSTRIALS
EV/EBITDA 70% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 3675% BELOW SECTOR MEDIAN
Gross Margin 61% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF DEC 31, 2024 (Q3 FY2024)
We rate ASTRAZENECA PLC (AZN) as a Buy with a composite score of 73.3/100 at a current price of $207.27. The stock scores above average across the majority of our six quantitative factors and ranks #31 out of 7,333 stocks in our universe, reflecting a favorable risk-reward profile.
The rating is primarily driven by strength in value (96th percentile) and quality (85th percentile), which together account for the majority of the composite score. All factors score above the 40th percentile, indicating no material weakness in the quantitative profile. We assign a Narrow Moat rating (66/100), Low uncertainty, and Exemplary capital allocation.
Key items to watch: quarterly earnings execution and sector-level competitive dynamics. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
ASTRAZENECA PLC holds an above-average position (#17 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 73.3/100 places it at rank #31 in our full 7,333-stock universe. With a $101.6B market capitalization, ASTRAZENECA PLC operates at meaningful scale within the Manufacturing sector, providing competitive advantages in distribution, procurement, and customer reach.
The outlook is moderately positive, with revenue expanding at 13% and favorable momentum (78th percentile) reflecting constructive market sentiment. The business shows steady execution, though the growth rate is below the levels typically associated with high-conviction growth stories. Momentum confirmation provides support for the current price level.
The margin cascade tells an important story: gross margins of 69% (+26.1pp vs sector) narrow to operating margins of 31% (+29.7pp vs sector) and net margins of 28.3%, yielding a gross-to-net conversion rate of 41%. This efficient conversion suggests well-controlled operating costs and limited margin leakage between the gross and net levels.
At a current price of $207.27, ASTRAZENECA PLC appears undervalued relative to its fundamentals. Our value factor score of 96/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The stock screens as attractively priced on a majority of these measures, suggesting the market may be underappreciating the underlying fundamentals.
The stock currently trades at a P/E of 45.1x (a 103% premium to the sector median of 22.3x), EV/EBITDA of 3.4x (discounted to peers), P/B of 3.9x, P/S of 1.2x. The above-sector P/E multiple suggests the market is pricing in superior growth or quality, which our analysis partially supports given strong quality metrics.
The stock's Buy rating (composite score 73.3/100) reflects broad-based quantitative strength, placing it in the top 20% of our 7,333-stock universe.
Gross margins of 69% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Returns on equity of 88.7% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
Revenue growth of 13% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A value factor score of 96/100 suggests the market is underpricing these fundamentals, creating a potential margin of safety for new investors.
We assign a Low uncertainty rating to ASTRAZENECA PLC. The company exhibits strong financial stability with a beta of 0.55, conservative leverage (37% D/E), and a stability factor in the 48th percentile. The predictable nature of the business model and solid financial position reduce the range of potential outcomes, giving us confidence in our fair value estimate.
Specific risk factors that inform our assessment include: low beta of 0.55 — while defensive, this may indicate limited upside participation in bull markets; elevated valuation multiple (P/E 45.1x) that leaves limited margin for error. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 48th percentile and quality factor at the 85th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 69% provide a buffer against cost pressures; large-cap scale ($101.6B) provides resilience; a 3.77% dividend yield anchors total return. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate ASTRAZENECA PLC's capital allocation as Exemplary. Management demonstrates a strong track record of balancing reinvestment with shareholder returns, evidenced by returns on equity of 88.7%, disciplined leverage (37% D/E), a 3.77% dividend yield. Exemplary allocators typically generate returns on equity above 20% while maintaining debt-to-equity below 50% — ASTRAZENECA PLC meets this high bar.
The balance sheet remains conservatively managed, providing financial flexibility for opportunistic investments while maintaining a margin of safety for shareholders. The company returns capital via a 3.77% dividend yield, and the combination of 69.6% return on assets and controlled leverage suggests management is deploying capital at rates well above the cost of capital — the hallmark of exemplary stewardship.
In summary, ASTRAZENECA PLC receives a Buy rating with a composite score of 73.3/100 (rank #31 of 7,333). Our quantitative framework assigns a Narrow Moat (66/100, trend: stable), Low uncertainty, and Exemplary capital allocation. The average factor score across quality, value, momentum, stability, and investment is 70/100.
Our analysis supports a constructive view on ASTRAZENECA PLC. The combination of identifiable competitive advantages, low uncertainty, and exemplary capital allocation creates a risk-reward profile that favors accumulation at current levels. We recommend investors consider adding this name to portfolios aligned with the stock's risk profile.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign ASTRAZENECA PLC a Narrow Moat rating with a composite moat score of 66/100. The ROIC-WACC spread of +54.7% is the primary signal of economic value creation. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that ASTRAZENECA PLC can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being margin superiority at 19/20.
The strongest moat sources are margin superiority (19/20) and economic value creation (15/20). GM 69% vs sector 43%, OM 31% vs sector 1%. ROIC 64.0% vs WACC 9.2% (spread +54.7%). These pillars form the core of ASTRAZENECA PLC's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include financial resilience (9.5/20) and growth durability (10.3/20). Interest coverage N/A, Net debt/EBITDA 1.0x. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect ASTRAZENECA PLC's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 69% providing a solid profitability foundation, operating margins of 31% reflecting effective cost management, moderate revenue growth of 13%. The margin cascade from 69% gross to 31% operating to 28.3% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that the profit engine is high-quality and likely sustainable, with the quality factor at the 85th percentile.
The margin profile shows gross margins of 69%, operating margins of 31%, net margins of 28.3%. Return metrics include ROE of 88.7% and ROA of 69.6%. Relative to the Manufacturing sector, gross margins are 26.1 percentage points above the sector median of 43%, and ROE of 88.7% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 37%, a dividend yield of 3.77%, revenue growth of 13%. The sector median D/E is 0%, putting ASTRAZENECA PLC at higher leverage than the typical peer. The combination of low leverage and healthy profitability provides significant financial resilience and strategic optionality.
A P/E of 45.1x leaves little room for execution misses — any earnings disappointment could trigger a sharp multiple compression.
Elevated short interest (89th percentile) indicates that sophisticated market participants are betting against the stock.
Above 50MA
37.18%
Net New Highs
+51081
ASTRAZENECA PLC (AZN) earns a Buy rating with a 73/100 composite score, ranking #32 among 7,333 U.S. stocks. Six-factor quantitative analysis of quality, value, momentum, investment efficiency, stability, and short interest.
ASTRAZENECA PLC (AZN) earns a Buy rating with a 74/100 composite score, ranking #25 among 7,333 U.S. stocks. Six-factor quantitative analysis of quality, value, momentum, investment efficiency, stability, and short interest.
The article discusses the potential "sell America" trade trend in 2026, where international investors may rotate out of U.S. assets due to concerns about tech valuations, trade policy, and Federal Reserve independence. The Vanguard Total International Stock ETF (VXUS) is highlighted as a diversified way to gain international exposure and hedge against a weakening dollar, with projections showing non-U.S. stocks could deliver 4.9-6.9% annualized returns over the next decade compared to 4-5% for U.S. stocks.
FDA grants Regenerative Medicine Advanced Therapy designation to Krystal Biotech’s KB707 in advanced or metastatic non small cell lung cancer. Decision is based on early clinical evidence of antitumor activity in a high need oncology setting. RMAT status is intended to support faster development and review timelines for qualifying therapies. For investors watching Krystal Biotech (NasdaqGS:KRYS), the RMAT designation adds a new angle to a story that has largely centered on rare skin...
AstraZeneca reported Q4 2025 sales of $15.50 billion, slightly beating consensus, with adjusted EPS of $2.12 exceeding expectations of $2.09. The company's cancer portfolio drove growth with 11% increase, led by strong performances from Tagrisso, Imfinzi, and Calquence. For 2026, AstraZeneca expects mid-to-high single-digit revenue growth and low double-digit EPS growth, with over 20 Phase 3 trial readouts anticipated. Shares rose 2.82% to $193.31.